» Articles » PMID: 26822005

Esterase-Sensitive Prodrugs with Tunable Release Rates and Direct Generation of Hydrogen Sulfide

Overview
Specialty Chemistry
Date 2016 Jan 30
PMID 26822005
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Prodrugs that release hydrogen sulfide upon esterase-mediated cleavage of an ester group followed by lactonization are described herein. By modifying the ester group and thus its susceptibility to esterase, and structural features critical to the lactonization rate, H2 S release rates can be tuned. Such prodrugs directly release hydrogen sulfide without the involvement of perthiol species, which are commonly encountered with existing H2 S donors. Additionally, such prodrugs can easily be conjugated to another non-steroidal anti-inflammatory agent, leading to easy synthesis of hybrid prodrugs. As a biological validation of the H2 S prodrugs, the anti-inflammatory effects of one such prodrug were examined by studying its ability to inhibit LPS-induced TNF-α production in RAW 264.7 cells. This type of H2 S prodrugs shows great potential as both research tools and therapeutic agents.

Citing Articles

Mercapto-NSAIDs generate a non-steroidal anti-inflammatory drug (NSAID) and hydrogen sulfide.

Gupta S, Mohite P, Chakrapani H Chem Sci. 2025; 16(11):4695-4702.

PMID: 39958646 PMC: 11826334. DOI: 10.1039/d4sc08525f.


A fluorogenic ROS-triggered hydrogen sulfide donor for alleviating cerebral ischemia-reperfusion injury.

Lu H, Zeng H, Wei W, Chen Y, Zhou Z, Ning X Theranostics. 2024; 14(19):7589-7603.

PMID: 39659579 PMC: 11626942. DOI: 10.7150/thno.100930.


Chemistry of Hydrogen Sulfide-Pathological and Physiological Functions in Mammalian Cells.

Andres C, Perez de la Lastra J, Juan C, Plou F, Perez-Lebena E Cells. 2023; 12(23).

PMID: 38067112 PMC: 10705518. DOI: 10.3390/cells12232684.


Nanomotor-based HS donor with mitochondrial targeting function for treatment of Parkinson's disease.

Zhao Z, Chen L, Yang C, Guo W, Huang Y, Wang W Bioact Mater. 2023; 31:578-589.

PMID: 37771932 PMC: 10522957. DOI: 10.1016/j.bioactmat.2023.09.001.


Plight of CORMs: The unreliability of four commercially available CO-releasing molecules, CORM-2, CORM-3, CORM-A1, and CORM-401, in studying CO biology.

Bauer N, Yuan Z, Yang X, Wang B Biochem Pharmacol. 2023; 214:115642.

PMID: 37321416 PMC: 10529722. DOI: 10.1016/j.bcp.2023.115642.


References
1.
Baskar R, Sparatore A, Del Soldato P, Moore P . Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur J Pharmacol. 2008; 594(1-3):1-8. DOI: 10.1016/j.ejphar.2008.07.029. View

2.
Szabo C . Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007; 6(11):917-35. DOI: 10.1038/nrd2425. View

3.
Fukushima N, Ieda N, Sasakura K, Nagano T, Hanaoka K, Suzuki T . Synthesis of a photocontrollable hydrogen sulfide donor using ketoprofenate photocages. Chem Commun (Camb). 2013; 50(5):587-9. DOI: 10.1039/c3cc47421f. View

4.
Shan D, Nicolaou M, Borchardt R, Wang B . Prodrug strategies based on intramolecular cyclization reactions. J Pharm Sci. 1997; 86(7):765-7. DOI: 10.1021/js970069d. View

5.
Milstien S, COHEN L . Rate acceleration by stereopopulation control: models for enzyme action. Proc Natl Acad Sci U S A. 1970; 67(3):1143-7. PMC: 283329. DOI: 10.1073/pnas.67.3.1143. View